A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

We evaluated the therapeutic efficacy of GC1118, a novel anti‐epidermal growth factor receptor (EGFR) monoclonal antibody, in recurrent glioblastoma (GBM) patients with EGFR amplification.

• Publication year

  2023

• Venue

  Cancer Medicine

• Publication date

  2023-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cam4.6213PMID 37537946PMCID 10469652
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors

  2023cited by this paper
• A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

  2023cited by this paper
• Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.

  2021cited by this paper
• Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas

  2021cited by this paper
• OMRT-3. Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment

  2021cited by this paper
• Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma.

  2020cited by this paper
• Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts

  2020cited by this paper
• Determining cell-type abundance and expression from bulk tissues with digital cytometry

  2019cited by this paper
• Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma

  2019cited by this paper
• EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand

  2019cited by this paper
• ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)

  2019cited by this paper
• Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts

  2019cited by this paper
• LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS

  2019cited by this paper
• A First‐in‐Human Phase I Study of GC1118, a Novel Anti‐Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors

  2019cited by this paper
• GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer

  2019cited by this paper
• Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

  2018cited by this paper
• Gamma-delta (γδ) T cells: friend or foe in cancer development?

  2018cited by this paper
• Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

  2017cited by this paper
• Epidermal growth factor receptor targeting and challenges in glioblastoma.

  2016cited by this paper
• Clonal evolution of glioblastoma under therapy

  2016cited by this paper
• Fast gene set enrichment analysis

  2016cited by this paper
• Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab

  2015cited by this paper
• GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands

  2015cited by this paper
• Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.

  2015cited by this paper
• Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

  2014cited by this paper
• Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.

  2014cited by this paper
• Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

  2014cited by this paper
• Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

  2013cited by this paper
• Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

  2013cited by this paper
• The somatic genomic landscape of glioblastoma.

  2013cited by this paper
• Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.

  2013cited by this paper
• Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

  2013cited by this paper
• Standards of care for treatment of recurrent glioblastoma--are we there yet?

  2013cited by this paper
• Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

  2013cited by this paper
• Absolute quantification of somatic DNA alterations in human cancer

  2012cited by this paper
• Sequence analysis of mutations and translocations across breast cancer subtypes

  2012cited by this paper
• Improved survival time trends for glioblastoma using the SEER 17 population-based registries

  2012cited by this paper
• GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

  2011cited by this paper
• Acquired MET Expression Confers Resistance to EGFR Inhibition In a Mouse Model of Glioblastoma Multiforme

  2011cited by this paper
• Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity

  2011cited by this paper
• Fast and SNP-tolerant detection of complex variants and splicing in short reads

  2010cited by this paper
• DEGseq: an R package for identifying differentially expressed genes from RNA-seq data

  2010cited by this paper
• Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

  2010cited by this paper
• Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

  2010cited by this paper
• The Sequence Alignment/Map format and SAMtools

  2009cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2009cited by this paper
• Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.

  2009cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines

  2007cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Theoretical and practical advances in genome halving

  2004cited by this paper
• Sample size tables for exact single‐stage phase II designs

  2001cited by this paper

• Pre-treatment subventricular zone perfusion asymmetry predicts vertical recurrence in glioblastoma

  2026cites this paper
• Race and “omic” data in glioma: A systematic review of contemporary research to explore the digital divide

  2025cites this paper
• Key genes altered in glioblastoma based on bioinformatics (Review)

  2025cites this paper
• Recent advances in molecular mechanisms of microRNAs in pathogenesis and resistance of treatment in glioblastoma

  2025cites this paper
• Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.

  2025cites this paper
• Immunotherapy and targeted therapy for high grade gliomas: current and future directions

  2025cites this paper
• Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials

  2024cites this paper
• Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma

  2024cites this paper
• Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma

  2024cites this paper
• Diagnostic challenges in complicated case of glioblastoma

  2024cites this paper
• Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities

  2024cites this paper
• Glioblastoma Therapy: Past, Present and Future

  2024cites this paper
• Novel Clinical Trials and Approaches in the Management of Glioblastoma

  2024influential citation
• Advanced tumor electric fields therapy: A review of innovative research and development and prospect of application in glioblastoma

  2024cites this paper
• Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies

  2024cites this paper
• A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

  2023cites this paper